Sinalac

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinalac

What is Sinalac? (Lactulose)

Property Description
Active ingredient Lactulose
Form Oral solution or syrup
Pharmacological class Osmotic laxative, Prebiotic
General Purpose Facilitates regular, softer bowel movements
Origin Synthetic disaccharide

What Type of Medicine is Sinalac (Lactulose)?

Sinalac is a medication characterized by its single active ingredient, Lactulose, which is clinically classified primarily as an osmotic laxative and secondarily as a prebiotic agent. This pharmacological designation signals that its primary function is achieved by modulating the contents of the bowel rather than being absorbed into the bloodstream. The preparation is consistently available as an oral solution or syrup, intended for the oral route of administration. As a hyperosmotic agent, Lactulose draws water into the colon. This action is clinically recognized for its use in patients requiring predictable relief from difficult bowel movements.


Composition and Origin: Is Lactulose Natural or Synthetic?

The core component of Sinalac is Lactulose, a synthetic disaccharide (a manufactured sugar derivative) dissolved in an aqueous vehicle. While derived from lactose, a naturally occurring milk sugar, Lactulose is intentionally synthesized to resist breakdown by human digestive enzymes in the small intestine. This unique chemical structure ensures the drug remains non-systemic, meaning the compound reaches the large intestine intact for its targeted action. Other popular brands containing this same formulation include Duphalac and Constilac. This specific, non-absorbed property ensures the drug works precisely at the site of its intended action with minimal overall systemic distribution.


General Purpose and Core Therapeutic Action

The general purpose of Sinalac is to facilitate easier and more regular bowel movements through localized action, making it a suitable option for individuals needing gentle, non-stimulant assistance. This is achieved through two complementary principles: osmotic activity, which pulls water into the colon to soften stool and increase bulk; and subsequent fermentation by colonic bacteria. This fermentation process creates organic acids that gently contribute to the stimulation of peristalsis (natural muscle movement) and create a locally beneficial environment in the large intestine. This action provides relief by addressing the underlying issue of hard, dry stool.

Regulatory References

  1. Lactulose: MedlinePlus Drug Information
  2. Lactulose - StatPearls - NCBI Bookshelf

What side effects are possible with Sinalac?

Sinalac: Possible Side Effects and Safety Information

Official regulatory documents structure the safety profile of Sinalac (lactulose) primarily around its gastrointestinal effects and the potential for electrolyte disturbances at high doses.


Adverse Reaction Scope

Classification Frequency Key Adverse Reactions
Very Common geq 1/10 Flatulence, Abdominal pain
Common geq 1/100 to < 1/10 Nausea, Vomiting, Diarrhea (especially at high dose)
Not Known Cannot be estimated Hypersensitivity reactions (e.g., rash, pruritus, urticaria)

Serious and Clinically Significant Reactions: The most significant safety concern is diarrhea resulting from the use of doses higher than those instructed. Severe or chronic diarrhea can lead to a disturbance of the electrolyte balance, particularly loss of potassium (hypokalaemia). Patients on high-dose or chronic therapy (longer than 6 months), especially the elderly or those in bad general condition, may require periodic electrolyte monitoring.


Safety-Related Restrictions and Limitations

Contraindications: Sinalac is formally contraindicated in patients with known hypersensitivity to the active substance, galactosemia (due to the presence of minor carbohydrates), suspected or confirmed gastrointestinal obstruction or subocclusive syndromes, acute inflammatory bowel disease (such as Crohn's disease or ulcerative colitis), or a risk of digestive perforation.

Population-Specific Considerations: The drug is administered with caution in individuals with diabetes due to its sugar content, and dose adjustment may be necessary when high doses are required. Patients with rare hereditary problems like galactose or fructose intolerance are advised against its use. Although animal studies show no evidence of fetal harm, use during pregnancy and lactation should be determined by a healthcare provider.


The overall safety profile indicates that while common gastrointestinal side effects are typical at the start of therapy, the primary risk involves dose-dependent diarrhea and the resulting electrolyte imbalance, which is a major factor in prescribing limitations and monitoring recommendations.

Overdose and Emergency Response

The official regulatory profile for an overdosage of Sinalac (Lactulose) defines the expected effects based on the drug's excessive osmotic activity, noting that no reports of accidental overdosage have been received. Overdosage is expected to result in diarrhea and abdominal cramps as the major clinical manifestations, with cases of excessive dosage also documenting the potential for nausea and vomiting.

The most serious outcome associated with uncorrected, excessive use is a significant fluid and electrolyte imbalance. This physiological disturbance results from the excessive loss of fluids and can manifest as specific abnormalities, including hypokalemia (low potassium) and hypernatremia (high sodium). These potential severe outcomes require careful consideration for vulnerable populations, such as elderly or debilitated patients, where regulators note the importance of periodic serum electrolyte monitoring during prolonged use.

Regulatory guidance mandates that the immediate action in the event of overdosage effects is the termination of the medication or dose reduction. Further management requires seeking medical attention for an unusual diarrheal condition or if symptoms of electrolyte imbalance occur. The treatment for overdosage is symptomatic and supportive, specifically focusing on the correction of any fluid and electrolyte disturbances arising from the sustained fluid loss.

Therapeutic Uses of Sinalac

Main Uses and Benefits of Sinalac

Sinalac is a medicinal product primarily utilized in the management of chronic constipation and certain conditions affecting brain function caused by liver disease. Its active component, lactulose, works as an osmotic laxative to facilitate regular bowel movements and improve gastrointestinal comfort.

Treatment of Constipation

The primary application of Sinalac is the relief of long-term constipation. It functions by drawing water into the colon, which softens the stool and increases its volume. This process stimulates intestinal movement (peristalsis), making transit easier and more predictable for the patient. Unlike some stimulant laxatives, its action is considered gentle, as it relies on the natural osmotic balance within the digestive tract.

Management of Hepatic Encephalopathy

Sinalac is also indicated for a condition known as hepatic encephalopathy. This is a decline in brain function that occurs when a damaged liver is unable to adequately remove toxins, such as ammonia, from the blood.

In this context, Sinalac provides several benefits:

  • Ammonia Reduction: It helps lower blood ammonia levels by creating an acidic environment in the gut. This acidity converts ammonia into ammonium, which is more easily trapped in the bowel and excreted.
  • Intestinal Transit: By increasing bowel movement frequency, it reduces the amount of time toxins spend in the intestines, further decreasing their absorption into the bloodstream.

Restoration of Bowel Rhythm

Beyond treating acute symptoms, Sinalac is used to help restore a regular physiological rhythm of defecation. This is particularly beneficial for individuals who have developed irregular habits due to lifestyle factors, dietary constraints, or prolonged immobilization. By maintaining a softer stool consistency, it also helps reduce the physical strain associated with bowel movements.

Regulatory References

  1. NCBI Bookshelf - NIH StatPearls overview of Lactulose

Eligibility and Restrictions for Use

Who can and cannot use Sinalac?

Sinalac (Lactulose) eligibility is strictly defined by regulatory bodies based on age, existing medical conditions, and physiological status.

The medicine is contraindicated and must not be used in individuals diagnosed with Galactosaemia or those with a known hypersensitivity to the drug. Use is also prohibited in patients with Gastrointestinal Obstruction, documented risk of Digestive Perforation, Acute Inflammatory Bowel Disease (such as Crohn’s disease), or painful abdominal syndromes of undetermined cause.


Population Eligibility Status Constraint / Condition
Established Use Adults and adolescents (for chronic constipation).
Use Not Established Safety and effectiveness have not been established in all pediatric populations (FDA).
Use with Caution Patients with Diabetes Mellitus (due to residual sugars) and those with conditions prone to electrolyte disorders (e.g., Renal/Hepatic impairment).
Conditional Use Pregnancy and Lactation are permitted if clearly needed, owing to the drug’s negligible systemic absorption.
Monitoring Required Older adults or debilitated patients receiving treatment for longer than six months require periodic control of serum electrolytes.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Sinalac (Lactulose) is structured around its non-systemic action and impact on fluid balance, rather than systemic metabolic pathways.

Documented Interaction Patterns

The regulatory information classifies interactions into efficacy-reducing effects and those related to electrolyte risk.

Interaction Mechanism Interacting Substances Official Regulatory Statement
Efficacy-Reducing Non-absorbable antacids, Anti-infective agents (e.g., Neomycin) May inhibit the desired colonic pH drop, potentially leading to a lack of desired treatment effect (antacids). Anti-infective agents may cause an inadequate response by destroying the necessary colonic bacteria.
Electrolyte Risk Thiazides, Steroids, Amphotericin B, Cardiac Glycosides Lactulose may increase the loss of potassium induced by these drugs. This potassium deficiency may subsequently increase the effect of cardiac glycosides.

Interaction-Related Restrictions and Caution

The product is contraindicated in patients who must follow a low-galactose diet due to the presence of small amounts of galactose and lactose in the solution. Other laxatives should be avoided during initial treatment phases. For diabetics, the product must be used with caution. Furthermore, official labeling requires periodic serum electrolyte monitoring for elderly or debilitated patients receiving the product for more than six months.

Mechanism of Action

Sinalac's mechanism of action is entirely local and non-systemic, relying on two distinct but complementary biological processes within the large intestine to affect the physical and muscular characteristics of the large intestine.

Osmotic Regulation of Colonic Fluid

This mechanism engages the colonic lumen water potential as its primary physical target. Lactulose is intentionally non-absorbed by the human digestive system, creating a high osmotic load once it reaches the colon. This load establishes an osmotic gradient that governs the transfer and retention of water from the surrounding circulation across the colonic epithelium into the bowel lumen. This physical process directly increases the hydration and volume of the fecal mass, which represents a key physiological consequence of the drug's action.

Microbial Fermentation and Motility Influence

A secondary, biochemical mechanism involves the action of the resident colonic microbiota. Specific bacteria metabolize the Lactulose, leading to the production of short-chain fatty acids ( SCFAs). The release of SCFAs lowers the local pH and increases the number of osmotically active particles, which provides a gentle, localized chemical stimulation. Both the physical volume expansion and the pH-mediated stimulation converge to influence propulsive motility (peristalsis) in the colon, resulting in the movement of the colonic contents.

Dosage and Administration Information

How to Use Sinalac

The administration of Sinalac (Lactulose) involves specific routes, forms, and schedules tailored to the condition being treated.

Administration Routes and Forms

Sinalac is principally administered via the oral route as a solution (syrup) or powder for solution. A specialized rectal route is used for acute management in specific clinical settings, such as portal-systemic encephalopathy (HE), utilizing a diluted retention enema.

Dosing Regimens and Titration

Indication Starting Dose (Adult) Maintenance Principle
Chronic Constipation 15 mL to 30 mL (10 g to 20 g) once daily. Dose is adjusted to achieve a goal of two to three soft stools per day.
HE Maintenance 30 mL to 50 mL three to four times daily. Adjusted to maintain the same target of 2–3 soft stools daily.

For most oral use, the dose is taken once daily, often at breakfast. The dose volume may be taken undiluted or mixed with water, milk, or fruit juice to improve palatability. The dose should be measured using a marked measuring device rather than a household spoon to ensure accuracy. The onset of action typically requires 24 to 48 hours of consistent administration. Pediatric dosing is based on specific age- or weight-based guidelines and does not exceed the adult maximum daily volume.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sinalac

Evidence for Use in Chronic Constipation

The research into Sinalac (Lactulose) for difficult bowel movements has primarily consisted of Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that synthesize the data from many studies. This research explored how symptoms change over time when Lactulose is given, particularly when compared to other studied therapeutic agents or a control group. Studies monitored outcomes related to physical discomfort, such as counting the frequency of bowel movements per week and objectively measuring changes in stool consistency using standardized scales. The research examined various populations, including the general adult population with chronic constipation, as well as some pediatric patients.

Findings from these studies describe patterns observed in the treatment groups, indicating changes measured during the study period, such as a reported increase in bowel movement frequency and measurements related to stool consistency. Research so far indicates that outcomes related to physiological strain or stress were observed during these short-term trials. Systematic reviews have noted that the quality of the studies varied, particularly among older trials, and that results were not always consistent when comparing Lactulose directly to other studied therapeutic agents.

Evidence for Use in Portal-Systemic/Hepatic Encephalopathy (HE)

Sinalac was studied in research exploring conditions characterized by fluctuating or episodic manifestations of neurocognitive impairment, which can be a complication of advanced liver disease. Research was evaluated in patients with both overt HE (more noticeable symptoms like confusion) and covert HE (minimal symptoms). The studies, which included RCTs and meta-analyses, monitored outcomes related to systemic or functional imbalance. Specifically, research examined how patient symptoms evolved and measured changes in blood ammonia levels, which is a key physiological biomarker. Evidence suggests that when comparing Lactulose to no intervention or placebo, data describe how symptoms evolved and patterns related to recurrence frequency in the studies observed.

Limitations and Research Gaps

A common observation across the evidence landscape for Sinalac is the variability in evidence quality, especially within the older studies. Follow-up durations were limited in many RCTs, creating a persistent gap in the understanding of long-term outcomes. The generalization of results is confined to the populations studied and the specific conditions under which they were conducted. Data for certain groups remain insufficient, such as frail older adults or those with highly specific comorbidities.

Key Studies & References Lactulose: A Review of its Therapeutic Effects in Constipation and Hepatic Encephalopathy

Frequently Asked Questions (FAQ)

Common questions about Sinalac (FAQ)


Q: What happens if I forget to take a dose of Sinalac?

A: Official instructions describe that if a dose is missed, it can be taken as soon as the person remembers. However, if it is nearly time for the next scheduled dose, the regulatory guidance is to skip the missed one. Product information states that the dose volume should not be doubled to compensate for the one that was missed.


Q: Is it normal to have mild stomach upset when first starting Sinalac?

A: Regulatory documents classify flatulence (gas) and mild abdominal discomfort as very common side effects that can occur when initiating treatment with Sinalac. This is a common pattern observed with the medication, and this mild effect typically lessens and disappears after the first few days of continued use.


Q: Can Sinalac be crushed, cut, or chewed?

A: Sinalac is typically provided as an oral solution or syrup and sometimes as a powder to be dissolved, rather than as a solid tablet. The liquid form is generally taken immediately, and official product guidance for the solution does not include information regarding crushing, cutting, or chewing the product.


Q: Can I stop taking Sinalac suddenly?

A: Official information does not detail a specific procedure for stopping use. However, if patients experience side effects like severe or chronic diarrhea, regulatory text notes that the standard clinical response is dose reduction or temporary cessation of treatment. The decision to stop treatment is generally based on the condition being addressed. Withdrawal symptoms are not typically noted in the drug's official product information when cessation occurs.


Q: What if I take Sinalac but don't feel any difference—is that normal?

A: The official product information notes that the onset of action for Sinalac is not immediate and typically requires 24 to 48 hours to produce the intended effect. If no difference is noticed after this initial period of consistent use, consulting a healthcare provider may be helpful if the expected onset of effect does not occur.


Q: Is Sinalac a type of antibiotic, or something else?

A: According to the United States National Library of Medicine (NLM), Sinalac (Lactulose) is classified primarily as a hyperosmotic laxative and also as a prebiotic agent. Its mechanism is localized to the colon and is entirely different from the action of an antibiotic medicine.


Q: Does Sinalac have a generic version available?

A: Yes, the active ingredient in Sinalac, known as Lactulose, is available as a generic medicine. The generic oral solution is available in addition to the various brand names.


Q: Are there any major food restrictions while using Sinalac?

A: The primary restriction described in regulatory documents is that Sinalac is contraindicated in patients required to follow a strict low-galactose diet. This is due to the small amounts of galactose and lactose sugars present in the solution. Otherwise, no major, non-galactose food restrictions are listed in official labeling.


Q: What is the longest period of time people typically use Sinalac for?

A: The length of time Sinalac is used varies significantly based on the condition being addressed. For chronic conditions like Hepatic Encephalopathy (HE), use may be long-term, potentially indefinite. For chronic constipation, the duration of use is not restricted in the FDA label and can be long-term, but it is typically subject to periodic monitoring.


Q: Do you need a prescription to get Sinalac?

A: In the United States, Sinalac (Lactulose) is a prescription-only medication that requires a doctor's authorization to obtain. Regulatory status may vary in other countries, where the active ingredient is sometimes available over-the-counter in pharmacies.


Q: Are there any known interactions between Sinalac and common supplements like Vitamin D?

A: Official documents generally do not list any specific problems regarding the mixing of Sinalac with common vitamins, herbal remedies, or nutritional supplements. Official guidance encourages patients to discuss all supplements being taken with their healthcare provider.


Q: What should I do if a side effect seems mild but bothersome?

A: If a mild, expected side effect such as gas or bloating becomes problematic or persistent, consulting a healthcare provider or pharmacist is described as the appropriate step. Regulatory information indicates that in some cases, side effects may be managed by reducing the dose or adjusting the time of administration.


Q: Why is Sinalac often prescribed for [Secondary condition mentioned in core text]?

A: For its use in the secondary condition, the drug works to reduce the absorption of ammonia in the colon. The metabolism of the drug by gut bacteria creates acidic substances that trap the ammonia, facilitating its elimination from the body in the stool.


Q: What kind of studies have been done on Sinalac?

A: The evidence supporting the use of Sinalac is mainly drawn from human trials, such as Randomized Controlled Trials (RCTs) and systematic reviews. These studies evaluate clinical outcomes like bowel movement frequency, stool consistency, and the levels of key biomarkers like blood ammonia.


Q: Is Sinalac known to interact with birth control pills?

A: Official regulatory information does not list a direct interaction between Sinalac and hormonal contraceptives. However, if the dose of Sinalac causes severe or chronic diarrhea, this severe gut disturbance could potentially reduce the absorption of oral contraceptive pills. Any need for additional precautions related to birth control is typically determined by a healthcare provider, based on the presence and severity of diarrhea.


Q: How long does Sinalac stay in your system after stopping?

A: Sinalac is poorly absorbed, with less than 3% entering the bloodstream. The vast majority of the dose is not absorbed and is eliminated in the stool after being metabolized by colonic bacteria. The small portion that does enter the bloodstream is excreted from the body unchanged via the urine, indicating that the drug has minimal overall systemic distribution.


Q: Does Sinalac affect blood sugar levels?

A: Official labeling advises caution for use in individuals with diabetes mellitus due to the small amounts of residual sugars (galactose and lactose) in the solution. However, studies evaluating typical doses in subjects with Type 2 diabetes indicated that blood glucose levels were generally not affected by oral intake.


Q: What is the difference between how Sinalac works and how a placebo works?

A: Sinalac has a specific, well-defined non-systemic mechanism of action that includes drawing water into the colon (osmotic effect) and microbial fermentation. A placebo, in contrast, is an inactive substance that is known to have no pharmacological effect or mechanism of action.


Q: Is the evidence for Sinalac based mainly on animal studies or human trials?

A: The research evidence used to establish the effectiveness of Sinalac is based primarily on human clinical trials, such as Randomized Controlled Trials. Animal studies are utilized mainly to support initial safety information regarding reproductive and toxicity data.


Q: What age groups is Sinalac generally intended for?

A: The medication is typically approved for use in adults and adolescents for its main indications. However, official FDA labeling does include specific dosing guidance for use in infants in certain situations, although the safety and effectiveness have not been established across all pediatric populations.


Q: Is there a possibility of an overdose with Sinalac (factual/descriptive)?

A: Regulatory documents describe that when higher-than-recommended dosages are used, the symptoms of an acute overdose are typically severe diarrhea and abdominal pain. Excessive fluid loss from severe diarrhea may lead to electrolyte imbalances, which typically require medical evaluation and management.


Q: Does Sinalac require any special monitoring by a doctor?

A: Official safety information describes the requirement for periodic monitoring of serum electrolytes (substances like potassium) for certain patient groups. This monitoring is typically recommended for older adults, debilitated patients, or anyone receiving the treatment for a long duration, generally longer than six months.


Q: How is Sinalac generally eliminated from the body?

A: The drug is eliminated mainly in the stool after being processed by bacteria in the colon, as it is poorly absorbed into the body. The small portion that does enter the bloodstream is excreted from the body unchanged via the urine, indicating that the drug has minimal overall systemic distribution.


Q: Are there any common misuses of Sinalac that people should be aware of?

A: Misuse is often related to the long-term use of unadjusted, high doses, which can lead to severe diarrhea and resulting fluid or electrolyte imbalances. The product is also contraindicated for use in patients with known or suspected gastrointestinal obstruction.

How should Sinalac be stored and disposed of?

Official Storage and Handling

The storage of Sinalac (Lactulose oral solution) must strictly adhere to regulatory requirements to maintain product stability and safety.

Detail Regulatory Requirement
Temperature Store at controlled room temperature, generally below 25 C to 30 C (86 F).
Protection Do not freeze the solution, and keep it in the original container with the cap tightly closed to protect it from light.
Child Safety Keep out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Sinalac should be discarded according to local requirements. It is officially advised not to dispose of the product via wastewater (sinks or toilets). Utilizing a drug take-back program or a pharmaceutical collection point is the preferred method for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sinalac found in:

A-Z Index: